AbbVie succeeds in its pursuit of Shire with a $53 billion deal which will give the U.S. pharma giant access to Shire's premium medicines for rare diseases, and, potentially, slash its tax bills. ... more 
AbbVie succeeds in its pursuit of Shire with a $53 billion deal which will give the U.S. pharma giant access to Shire's premium medicines for rare diseases, and, potentially, slash its tax bills. David Pollard reports. less 
1 / 21
Reuters Videos
Fri, Jul 18, 2014 11:10 AM EDT